Categories: Wire Stories

Elpiscience Announces Three Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

SHANGHAI & SUZHOU, China & GERMANTOWN, Md.–(BUSINESS WIRE)–Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego. The posters will highlight its studies on three innovative molecules including a first-in-class NKG2A/NKG2C dual-targeting antibody ES015, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014 which has been proven to be able to deliver TGFβ “trap” to CD39-expressing immune and stroma cells to reshape tumor microenvironment and rejuvenates antitumor immunity.


Poster presentation details:

Title: Selective delivery of TGFβ “trap” to CD39-expressing immune and stroma cells reshapes tumor microenvironment and rejuvenates antitumor immunity

Abstract Number: 453

Date and time: November 3, 2023; 9 am –7 pm PDT

Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response

Abstract Number: 498

Date and time: November 4, 2023; 9 am –8:30 pm PDT

Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: ES008-a, a high affinity LILRB1 specific blocking antibody activates multiple immune cells to fight cancers

Abstract Number: 510

Date and time: November 4, 2023; 9 am –8:30 pm PDT

Location: Exhibit Halls A and B1 – San Diego Convention Center

About Elpiscience

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.

For more information, please visit: www.elpiscience.com

Contacts

BD inquiries: BD@elpiscience.com
Media inquiries: PR@elpiscience.com

Alex

Recent Posts

AI Solution to Manage Complex Document Processes for the Private and Public Sector Driven by Arteria AI & TCAP

NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE)--#AI--The Commercial Advisory Partnership (TCAP) is proud to support the…

58 mins ago

Equip Super Completes Transition to Northern Trust for Asset Servicing Solutions

MELBOURNE, Australia--(BUSINESS WIRE)--#assetmanagement--Northern Trust (Nasdaq: NTRS) today announced that it will provide asset servicing solutions,…

59 mins ago

James Hardie Industries Announces Fourth Quarter And Fiscal Year 2024 Results

Record Net Sales of US$3.9 Billion for the Fiscal Year Record Adjusted Net Income of…

2 hours ago

INVNT™ Announced as Sponsor and Co-Producer of Discovery Stage at SXSW Sydney® 2024

Also named as an endorsed Creative Experiential Partner for the 2024 event SYDNEY--(BUSINESS WIRE)--INVNT™, the…

3 hours ago

Alcoa Announces Update on Acquisition of Alumina Limited

Alcoa and Alumina enter into Amended Scheme of Implementation Deed Allan Gray Australia reiterates support…

3 hours ago

SHI International Corp. Announces Definitive Agreement to Acquire Locuz Enterprise Solutions Limited, an Indian Cybersecurity and Digital Transformation Services Company

SOMERSET, N.J.--(BUSINESS WIRE)--SHI International Corp., a leading global provider of innovative technology solutions, today announced…

4 hours ago